| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Cynthia McLaughlin
Michael Rose
Jenna Brashear
| Share Statistics | CNTB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $115.9 | $282.4 | 23% |
|
| Shares Out (Mil) | 62.9 | 54.0 | 53% |
|
| Institutional Ownership | 58.2% | 93.1% | 38% |
|
| Float (Mil) | 21.1 | 42.2 | 30% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,366 | 482 | 78% |
|
| Price Change (52-week) |
3.4% | 59.9% | 49% |
|
| Growth | CNTB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 14.2% | (10.1%) | 62% |
|
| EPS (5yr) | 32.2% | 15.9% | 83 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.260) | ($1.002) | ($0.746) | |
| Month Ago EPS | ($0.280) | ($1.046) | ($0.784) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.255) | ($1.062) | ($0.993) | |
| Year/Year Chg | (5.5%) | 0.5% | (37.0%) | |
| Financials | CNTB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($69) | ($43) | 14% |
|
| EPS (TTM) | ($1.193) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $2 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $129 | $190 | 23% |
|
| Valuation | CNTB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.28 | 2.84 | 74% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CNTB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (109.3%) | (47.7%) | 5% |
|
| ROE | (140.5%) | (55.0%) | 6% |
|
| Liabilities to Assets | 38.2% | 29.8% | 29% |
|
| F-Score | 2 | 3 | 7% |
|
Connect Biopharma Holdings Limited did not pass any screens on 9/4/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
